Showing results (151-160 of 218) with videos related to

Sort By:
Pageof 22
Nature Aging|April 4, 2022
DNA methylation clocks tick in naked mole rats but queens age more slowly than nonbreedersSteve Horvath, Amin Haghani, Nicholas Macoretta, et al.
Cell Reports|September 14, 2023
CD44 correlates with longevity and enhances basal ATF6 activity and ER stress resistanceMasaki Takasugi, Naoko Ohtani, Kazuaki Takemura, et al.
Cell Reports|July 30, 2020
Beaver and Naked Mole Rat Genomes Reveal Common Paths to LongevityXuming Zhou, Qianhui Dou, Guangyi Fan, et al.
The EMBO Journal|June 13, 2022
Characterization of naked mole-rat hematopoiesis reveals unique stem and progenitor cell patterns and neotenic traitsStephan Emmrich, Alexandre Trapp, Frances Tolibzoda Zakusilo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2004
Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19Leonard Reyno, Lesley Seymour, Dongsheng Tu, et al.
Gynecologic Oncology|July 13, 2017
A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancerRebecca Kristeleit, Irina Davidenko, Vadim Shirinkin, et al.
Nature|August 23, 2023
Increased hyaluronan by naked mole-rat Has2 improves healthspan in miceZhihui Zhang, Xiao Tian, J Yuyang Lu, et al.
Stem Cell Reports|November 7, 2017
Naked Mole Rat Cells Have a Stable Epigenome that Resists iPSC ReprogrammingLi Tan, Zhonghe Ke, Gregory Tombline, et al.
Clinical Colorectal Cancer|July 29, 2014
Randomized phase II open-label study of mFOLFOX6 in combination with linifanib or bevacizumab for metastatic colorectal cancerBert H O'Neil, Calin Cainap, Eric Van Cutsem, et al.
British Journal of Cancer|July 28, 2019
Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancerVera Gorbunova, J Thaddeus Beck, Ralf-Dieter Hofheinz, et al.
Pageof 22